Nine months after reports of a security review by U.S./UK investment screening officials, the acquisition by a company with Chinese links of a U.S./UK pharmaceutical company has been approved by both governments.

You don't have access to this post on China Trade Monitor at the moment, but if you upgrade your account you'll be able to see the whole thing, as well as all the other posts in the archive! Subscribing only takes a few seconds and will give you immediate access.

This post is for subscribers only

Subscribe now